Journal Article

Propofol enhancement of slow wave sleep to target the nexus of geriatric depression and cognitive dysfunction: protocol for a phase I open label trial

Ching, ShiNung, Schweiger, Julia, Rios, Rachel Lynn, Nguyen, Thomas, Kafashan, MohammadMehdi, Farber, Nuri B, Reynolds, Charles F, Lin, Nan, Palanca, Ben Julian Agustin, Perez, Aris, Lenze, Eric J, Greenspan, Robby, Quigley, Allyson, Patel, Jay, Green, Michael, Koenig, Adam, Lucey, Brendan P, Kraenzle, Elliott, Hyche, Orlandrea, Wulfers, Jennifer, Simon, Hilary, Zassenhaus, Sriram, Foster, Olivia, Robeck, Matthew, K Labonte, Alyssa, Smith, S Kendall, Salvatore, Sofia, Janssen-Scott, Tiffany

2024

Overview

IntroductionLate-life treatment-resistant depression (LL-TRD) is common and increases risk for accelerated ageing and cognitive decline. Impaired sleep is common in LL-TRD and is a risk factor for cognitive decline. Slow wave sleep (SWS) has been implicated in key processes including synaptic plasticity and memory. A deficiency in SWS may be a core component of depression pathophysiology. The anaesthetic propofol can induce electroencephalographic (EEG) slow waves that resemble SWS. Propofol may enhance SWS and oral antidepressant therapy, but relationships are unclear. We hypothesise that propofol infusions will enhance SWS and improve depression in older adults with LL-TRD. This hypothesis has been supported by a recent small case series.Methods and analysisSWIPED (Slow Wave Induction by Propofol to Eliminate Depression) phase I is an ongoing open-label, single-arm trial that assesses the safety and feasibility of using propofol to enhance SWS in older adults with LL-TRD. The study is enrolling 15 English-speaking adults over age 60 with LL-TRD. Participants will receive two propofol infusions 2–6 days apart. Propofol infusions are individually titrated to maximise the expression of EEG slow waves. Preinfusion and postinfusion sleep architecture are evaluated through at-home overnight EEG recordings acquired using a wireless headband equipped with dry electrodes. Sleep EEG recordings are scored manually. Key EEG measures include sleep slow wave activity, SWS duration and delta sleep ratio. Longitudinal changes in depression, suicidality and anhedonia are assessed. Assessments are performed prior to the first infusion and up to 10 weeks after the second infusion. Cognitive ability is assessed at enrolment and approximately 3 weeks after the second infusion.Ethics and disseminationThe study was approved by the Washington University Human Research Protection Office. Recruitment began in November 2022. Dissemination plans include presentations at scientific conferences, peer-reviewed publications and mass media. Positive results will lead to a larger phase II randomised placebo-controlled trial.Trial registration numberNCT04680910.

• Publisher: British Medical Journal Publishing Group,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Adult anaesthesia / Aged / Anesthesia / Anesthetics, Intravenous - administration & dosage / Antidepressants / Clinical trials / Clinical Trials, Phase I as Topic / Cognition / Cognitive Dysfunction - drug therapy / Cognitive Dysfunction - etiology / Dementia / Depression & mood disorders / Depressive Disorder, Treatment-Resistant - drug therapy / Dopamine / Drug therapy / Electroencephalography / Executive function / Eye movements / Female / GERIATRIC MEDICINE / Humans / Insomnia / Male / Memory / Mental depression / Mental Health / Middle Aged / Older people / Pathophysiology / Patients / Pilot projects / Propofol - administration & dosage / Remission (Medicine) / Sleep / Sleep medicine / Sleep, Slow-Wave - drug effects